The Prevention of Early Asthma in Kids study: Design, rationale and methods for the Childhood Asthma Research and Education network

Theresa W. Guilbert, Wayne J Morgan, Marzena Krawiec, Robert F. Lemanske, Chris Sorkness, Stanley J. Szefler, Gary Larsen, Joseph D. Spahn, Robert S. Zeiger, Gregory Heldt, Robert C. Strunk, Leonard B. Bacharier, Gordon R. Bloomberg, Vernon M. Chinchilli, Susan J. Boehmer, Elizabeth A. Mauger, David T. Mauger, Lynn M. Taussig, Fernando Martinez

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Pediatric asthma remains an important public health concern as its prevalence and cost to the health care system is rising. In order to promote innovative research in asthma therapies, the National Heart, Lung and Blood Institute created the Childhood Asthma Research and Education Network in 1999. As its first study, the steering committee of the Childhood Asthma Research and Education Network designed a randomized clinical trial to determine if persistent asthma could be prevented in children at a high risk to develop the disease. This communication presents the design of its first clinical trial, the Prevention of Asthma in Kids (PEAK) trial and the organization of the Childhood Asthma Research and Education Network that developed and implemented this trial. Studies of the natural history of asthma have shown that, in persistent asthma, the initial asthma-like symptoms and loss of lung function occur predominately during the first years of life. Therefore, in the Prevention of Asthma in Kids study, children 2 and 3 years old with a positive asthma predictive index were randomized to twice daily treatment with fluticasone 88 μg or placebo via metered-dose inhaler and Aerochamber® for 2 years. The double blind treatment period was followed by a 1-year observational period. Lung function was measured by spirometry and oscillometry technique at 4-month intervals throughout the study. Bronchodilator reversibility and exhaled nitric oxide (ENO) studies were performed at the end of the treatment and observation periods. The primary outcome measure was the number of asthma-free days. Other secondary outcomes included number of exacerbations, use of asthma medications and lung function. These measures were chosen to reflect the progression of the disease from intermittent wheezing to persistent asthma and measurement of the extent of airflow limitation and airway reactivity.

Original languageEnglish (US)
Pages (from-to)286-310
Number of pages25
JournalControlled Clinical Trials
Volume25
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Asthma
Education
Research
Lung
Oscillometry
National Heart, Lung, and Blood Institute (U.S.)
Metered Dose Inhalers
Bronchodilator Agents
Spirometry
Respiratory Sounds
Therapeutics
Disease Progression
Nitric Oxide
Randomized Controlled Trials
Public Health
Placebos
Observation
Outcome Assessment (Health Care)
Clinical Trials
Organizations

Keywords

  • Allergens
  • Asthma predictive index
  • Atopy
  • Bronchial hyperresponsiveness
  • Clinical trials
  • Early childhood asthma
  • Exhaled nitric oxide
  • Fluticasone
  • Glucocorticoids
  • Intermittent wheezing
  • Oscillometry
  • Prevention of asthma
  • Research network
  • Spirometry

ASJC Scopus subject areas

  • Pharmacology

Cite this

The Prevention of Early Asthma in Kids study : Design, rationale and methods for the Childhood Asthma Research and Education network. / Guilbert, Theresa W.; Morgan, Wayne J; Krawiec, Marzena; Lemanske, Robert F.; Sorkness, Chris; Szefler, Stanley J.; Larsen, Gary; Spahn, Joseph D.; Zeiger, Robert S.; Heldt, Gregory; Strunk, Robert C.; Bacharier, Leonard B.; Bloomberg, Gordon R.; Chinchilli, Vernon M.; Boehmer, Susan J.; Mauger, Elizabeth A.; Mauger, David T.; Taussig, Lynn M.; Martinez, Fernando.

In: Controlled Clinical Trials, Vol. 25, No. 3, 06.2004, p. 286-310.

Research output: Contribution to journalArticle

Guilbert, TW, Morgan, WJ, Krawiec, M, Lemanske, RF, Sorkness, C, Szefler, SJ, Larsen, G, Spahn, JD, Zeiger, RS, Heldt, G, Strunk, RC, Bacharier, LB, Bloomberg, GR, Chinchilli, VM, Boehmer, SJ, Mauger, EA, Mauger, DT, Taussig, LM & Martinez, F 2004, 'The Prevention of Early Asthma in Kids study: Design, rationale and methods for the Childhood Asthma Research and Education network', Controlled Clinical Trials, vol. 25, no. 3, pp. 286-310. https://doi.org/10.1016/j.cct.2004.03.002
Guilbert, Theresa W. ; Morgan, Wayne J ; Krawiec, Marzena ; Lemanske, Robert F. ; Sorkness, Chris ; Szefler, Stanley J. ; Larsen, Gary ; Spahn, Joseph D. ; Zeiger, Robert S. ; Heldt, Gregory ; Strunk, Robert C. ; Bacharier, Leonard B. ; Bloomberg, Gordon R. ; Chinchilli, Vernon M. ; Boehmer, Susan J. ; Mauger, Elizabeth A. ; Mauger, David T. ; Taussig, Lynn M. ; Martinez, Fernando. / The Prevention of Early Asthma in Kids study : Design, rationale and methods for the Childhood Asthma Research and Education network. In: Controlled Clinical Trials. 2004 ; Vol. 25, No. 3. pp. 286-310.
@article{549b5a05e8d44d7a86ae45d61f54f712,
title = "The Prevention of Early Asthma in Kids study: Design, rationale and methods for the Childhood Asthma Research and Education network",
abstract = "Pediatric asthma remains an important public health concern as its prevalence and cost to the health care system is rising. In order to promote innovative research in asthma therapies, the National Heart, Lung and Blood Institute created the Childhood Asthma Research and Education Network in 1999. As its first study, the steering committee of the Childhood Asthma Research and Education Network designed a randomized clinical trial to determine if persistent asthma could be prevented in children at a high risk to develop the disease. This communication presents the design of its first clinical trial, the Prevention of Asthma in Kids (PEAK) trial and the organization of the Childhood Asthma Research and Education Network that developed and implemented this trial. Studies of the natural history of asthma have shown that, in persistent asthma, the initial asthma-like symptoms and loss of lung function occur predominately during the first years of life. Therefore, in the Prevention of Asthma in Kids study, children 2 and 3 years old with a positive asthma predictive index were randomized to twice daily treatment with fluticasone 88 μg or placebo via metered-dose inhaler and Aerochamber{\circledR} for 2 years. The double blind treatment period was followed by a 1-year observational period. Lung function was measured by spirometry and oscillometry technique at 4-month intervals throughout the study. Bronchodilator reversibility and exhaled nitric oxide (ENO) studies were performed at the end of the treatment and observation periods. The primary outcome measure was the number of asthma-free days. Other secondary outcomes included number of exacerbations, use of asthma medications and lung function. These measures were chosen to reflect the progression of the disease from intermittent wheezing to persistent asthma and measurement of the extent of airflow limitation and airway reactivity.",
keywords = "Allergens, Asthma predictive index, Atopy, Bronchial hyperresponsiveness, Clinical trials, Early childhood asthma, Exhaled nitric oxide, Fluticasone, Glucocorticoids, Intermittent wheezing, Oscillometry, Prevention of asthma, Research network, Spirometry",
author = "Guilbert, {Theresa W.} and Morgan, {Wayne J} and Marzena Krawiec and Lemanske, {Robert F.} and Chris Sorkness and Szefler, {Stanley J.} and Gary Larsen and Spahn, {Joseph D.} and Zeiger, {Robert S.} and Gregory Heldt and Strunk, {Robert C.} and Bacharier, {Leonard B.} and Bloomberg, {Gordon R.} and Chinchilli, {Vernon M.} and Boehmer, {Susan J.} and Mauger, {Elizabeth A.} and Mauger, {David T.} and Taussig, {Lynn M.} and Fernando Martinez",
year = "2004",
month = "6",
doi = "10.1016/j.cct.2004.03.002",
language = "English (US)",
volume = "25",
pages = "286--310",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - The Prevention of Early Asthma in Kids study

T2 - Design, rationale and methods for the Childhood Asthma Research and Education network

AU - Guilbert, Theresa W.

AU - Morgan, Wayne J

AU - Krawiec, Marzena

AU - Lemanske, Robert F.

AU - Sorkness, Chris

AU - Szefler, Stanley J.

AU - Larsen, Gary

AU - Spahn, Joseph D.

AU - Zeiger, Robert S.

AU - Heldt, Gregory

AU - Strunk, Robert C.

AU - Bacharier, Leonard B.

AU - Bloomberg, Gordon R.

AU - Chinchilli, Vernon M.

AU - Boehmer, Susan J.

AU - Mauger, Elizabeth A.

AU - Mauger, David T.

AU - Taussig, Lynn M.

AU - Martinez, Fernando

PY - 2004/6

Y1 - 2004/6

N2 - Pediatric asthma remains an important public health concern as its prevalence and cost to the health care system is rising. In order to promote innovative research in asthma therapies, the National Heart, Lung and Blood Institute created the Childhood Asthma Research and Education Network in 1999. As its first study, the steering committee of the Childhood Asthma Research and Education Network designed a randomized clinical trial to determine if persistent asthma could be prevented in children at a high risk to develop the disease. This communication presents the design of its first clinical trial, the Prevention of Asthma in Kids (PEAK) trial and the organization of the Childhood Asthma Research and Education Network that developed and implemented this trial. Studies of the natural history of asthma have shown that, in persistent asthma, the initial asthma-like symptoms and loss of lung function occur predominately during the first years of life. Therefore, in the Prevention of Asthma in Kids study, children 2 and 3 years old with a positive asthma predictive index were randomized to twice daily treatment with fluticasone 88 μg or placebo via metered-dose inhaler and Aerochamber® for 2 years. The double blind treatment period was followed by a 1-year observational period. Lung function was measured by spirometry and oscillometry technique at 4-month intervals throughout the study. Bronchodilator reversibility and exhaled nitric oxide (ENO) studies were performed at the end of the treatment and observation periods. The primary outcome measure was the number of asthma-free days. Other secondary outcomes included number of exacerbations, use of asthma medications and lung function. These measures were chosen to reflect the progression of the disease from intermittent wheezing to persistent asthma and measurement of the extent of airflow limitation and airway reactivity.

AB - Pediatric asthma remains an important public health concern as its prevalence and cost to the health care system is rising. In order to promote innovative research in asthma therapies, the National Heart, Lung and Blood Institute created the Childhood Asthma Research and Education Network in 1999. As its first study, the steering committee of the Childhood Asthma Research and Education Network designed a randomized clinical trial to determine if persistent asthma could be prevented in children at a high risk to develop the disease. This communication presents the design of its first clinical trial, the Prevention of Asthma in Kids (PEAK) trial and the organization of the Childhood Asthma Research and Education Network that developed and implemented this trial. Studies of the natural history of asthma have shown that, in persistent asthma, the initial asthma-like symptoms and loss of lung function occur predominately during the first years of life. Therefore, in the Prevention of Asthma in Kids study, children 2 and 3 years old with a positive asthma predictive index were randomized to twice daily treatment with fluticasone 88 μg or placebo via metered-dose inhaler and Aerochamber® for 2 years. The double blind treatment period was followed by a 1-year observational period. Lung function was measured by spirometry and oscillometry technique at 4-month intervals throughout the study. Bronchodilator reversibility and exhaled nitric oxide (ENO) studies were performed at the end of the treatment and observation periods. The primary outcome measure was the number of asthma-free days. Other secondary outcomes included number of exacerbations, use of asthma medications and lung function. These measures were chosen to reflect the progression of the disease from intermittent wheezing to persistent asthma and measurement of the extent of airflow limitation and airway reactivity.

KW - Allergens

KW - Asthma predictive index

KW - Atopy

KW - Bronchial hyperresponsiveness

KW - Clinical trials

KW - Early childhood asthma

KW - Exhaled nitric oxide

KW - Fluticasone

KW - Glucocorticoids

KW - Intermittent wheezing

KW - Oscillometry

KW - Prevention of asthma

KW - Research network

KW - Spirometry

UR - http://www.scopus.com/inward/record.url?scp=2442587672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442587672&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2004.03.002

DO - 10.1016/j.cct.2004.03.002

M3 - Article

C2 - 15157730

AN - SCOPUS:2442587672

VL - 25

SP - 286

EP - 310

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 3

ER -